Strong Operating Cash Flow in Health Care
Companies with positive operating cash flow, demonstrating that core business operations generate real cash regardless of accounting adjustments.
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
75 Companies Meeting Criteria
Showing 1–50 of 75 companies, ranked by Operating CF.
| # | Company | Operating CF | Free Cash Flow | Net Income |
|---|---|---|---|---|
| 1 | JNJJohnson & Johnson | $24.5B | $19.7B | $25.1B |
| 2 | ABBVAbbVie | $19.0B | $17.8B | $2.4B |
| 3 | LLYLilly (Eli) | $16.8B | - | $18.4B |
| 4 | MRKMerck & Co. | $16.5B | $12.4B | $19.0B |
| 5 | BMYBristol Myers Squibb | $14.2B | $12.8B | $6.0B |
| 6 | PFEPfizer | $11.7B | $9.1B | $9.8B |
| 7 | GILDGilead Sciences | $10.0B | $9.5B | $8.1B |
| 8 | AMGNAmgen | $10.0B | $8.1B | $7.0B |
| 9 | REGNRegeneron Pharmaceuticals | $5.0B | $4.1B | $4.6B |
| 10 | VRTXVertex Pharmaceuticals | $3.6B | $3.2B | $3.7B |
| 11 | ZTSZoetis | $2.9B | $2.3B | $2.7B |
| 12 | RPRXRoyalty Pharma plc | $2.5B | - | $859M |
| 13 | VTRSViatris | $2.3B | $1.9B | -$634M |
| 14 | BIIBBiogen | $2.2B | $2.1B | $1.6B |
| 15 | TEVATEVA PHARMACEUTICAL INDUSTRIES LTD | $1.6B | $1.1B | -$1.6B |
| 16 | UTHRUnited Therapeutics | $1.6B | $1.0B | $1.3B |
| 17 | INCYIncyte | $1.4B | $287M | $1.2B |
| 18 | BHCBausch Health Companies Inc. | $1.4B | $1.0B | $362M |
| 19 | JAZZJazz Pharmaceuticals | $1.4B | $1.3B | -$368M |
| 20 | ONCBeOne Medicines Ltd. | $1.1B | $942M | -$645M |
| 21 | EXELExelixis | $884M | $876M | $678M |
| 22 | BMRNBioMarin Pharmaceutical | $828M | $725M | $520M |
| 23 | NBIXNeurocrine Biosciences | $783M | $749M | $428M |
| 24 | PTCTPTC Therapeutics, Inc. | $711M | $702M | -$363M |
| 25 | OGNOrganon & Co. | $700M | $538M | $501M |
| 26 | HALOHalozyme | $652M | $645M | $595M |
| 27 | ELANElanco | $560M | $284M | $36M |
| 28 | ALNYALNYLAM PHARMACEUTICALS, INC. | $524M | $465M | -$278M |
| 29 | ALKSAlkermes plc | $521M | $480M | $339M |
| 30 | HRMYHarmony Biosciences Holdings, Inc. | $348M | $348M | $145M |
| 31 | BCRXBIOCRYST PHARMACEUTICALS INC | $347M | $345M | -$89M |
| 32 | AMRXAmneal Pharmaceuticals, Inc. | $340M | $270M | $49M |
| 33 | COLLCollegium Pharmaceutical, Inc. | $329M | $328M | $69M |
| 34 | PBHPrestige Consumer Healthcare | $249M | $239M | $215M |
| 35 | TBPHTheravance Biopharma, Inc. | $239M | $238M | -$56M |
| 36 | PRGOPerrigo | $239M | $145M | -$52M |
| 37 | CPRXCatalyst Pharmaceuticals Partners, Inc. | $209M | $209M | $164M |
| 38 | KRYSKrystal Biotech, Inc. | $201M | $189M | $89M |
| 39 | INVAInnoviva, Inc. | $197M | $196M | $23M |
| 40 | ANIPANI Pharmaceuticals, Inc. | $185M | $171M | -$19M |
| 41 | ARWRArrowhead Pharmaceuticals | $180M | $157M | -$2M |
| 42 | EBSEmergent BioSolutions Inc. | $171M | $157M | $76M |
| 43 | AMPHAmphstar Pharmaceuticals, Inc. | $156M | $121M | $160M |
| 44 | PCRXPacira BioSciences, Inc. | $152M | $137M | -$100M |
| 45 | CORTCorcept Therapeutics Incorporated | $142M | $142M | $141M |
| 46 | KNSAKiniksa Pharmaceuticals International, plc | $138M | $136M | -$43M |
| 47 | AUPHAurinia Pharmaceuticals Inc. | $136M | - | $6M |
| 48 | IRWDIRONWOOD PHARMACEUTICALS INC | $127M | $127M | $880,000 |
| 49 | RGENRepligen | $117M | $94M | -$26M |
| 50 | FTREFortrea | $114M | $88M | -$1.0B |
Understanding Operating Cash Flow
Operating cash flow (OCF) measures cash generated from a company's core business activities. Unlike net income, OCF strips out non-cash items like depreciation and stock-based compensation, revealing the actual cash a business produces. Consistently positive OCF is essential for funding operations, investments, and shareholder returns without relying on external financing.
Operating Cash Flow > $0
Results are based on SEC EDGAR filings. Companies with missing, unreliable, or extreme outlier values are excluded from screening.
Related Rankings
See the top companies ranked by these related metrics